No quarterly revenue total was found in GT Biopharma, Inc.'s SEC filings.
GT Biopharma, Inc. (GTBP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-4.52M
+85.0% vs year-ago quarter
Operating cash flow
$-4.26M
-41.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.12
+98.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
45.11M
+1168.0% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GTBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 109657
- Former names
- GT Biopharma, Inc. (until Oct 20, 2026); OXIS INTERNATIONAL INC (until Jul 25, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.5M | -$2.8M | -$5.6M | -$3.4M | -$1.5M |
| Net income | -$4.5M | -$2.8M | -$5.7M | $8.3M | -$30.2M |
| Diluted EPS | -$0.12 | -$0.11 | -$0.58 | $1.04 | -$10.92 |
| Operating cash flow | -$4.3M | -$2.5M | -$4.0M | -$3.7M | -$3.0M |
| Total assets | — | — | $8.1M | $4.3M | $7.1M |
| Total liabilities | — | — | — | $1.3M | $31.0M |
| Stockholders' equity | $3.6M | $7.6M | $5.8M | $3.0M | -$25.9M |
| Cash and investments | $5.0M | $8.9M | $6.8M | $2.5M | $5.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 25, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Sep 21, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Sep 3, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 883 GT Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.